Display Settings:

Format

Send to:

Choose Destination

    J Cardiovasc Electrophysiol. 2008 Mar;19(3):301-8. Epub 2007 Nov 21.

    Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome.

    Fish JM, Antzelevitch C.

    Masonic Medical Research Laboratory, Utica, New York 13501-1787, USA. fish@mmrl.edu

    INTRODUCTION: T-wave alternans (TWA) is characterized by beat to beat alteration in the amplitude, polarity and/or morphology of the electrocardiographic T wave. TWA has been reported in patients with the Brugada syndrome (BS) and is thought to be associated with an increased risk for development of VT/VF. The cellular mechanisms involved are not well-defined and are the subject of this investigation. METHODS: In an experimental model of BS composed of an arterially perfused canine right ventricular wedge preparation pretreated with verapamil (1-7 microM), an agent with sodium and calcium channel blocking activity, we simultaneously recorded transmembrane action potentials from two epicardial and one endocardial site, together with a pseudo-ECG. At select frequencies, verapamil induced alternans of both the T-wave amplitude and QT interval. The alternans resulted from either loss of the epicardial action potential dome on alternate beats or concealed phase 2 reentry within the epicardium on alternate beats. Loss of the epicardial action potential dome significantly increased transmural dispersion of repolarization (TDR) when compared with control (18.0 +/- 7.8 ms vs. 82.1 +/- 16.8 ms, P < 0.001, n = 8). During alternans, TDR was greater in beats displaying a more negative T wave (55.1 +/- 45.2 ms vs. 89.8 +/- 39.3 ms, P < 0.001, n = 22 data points from 8 preparations). CONCLUSIONS: Our data indicate that TWA in an experimental model of the Brugada syndrome is due to alternating loss of the epicardial AP dome and/or concealed phase 2 reentry, both serving to increase TDR and create the substrate for the development VT/VF.

    PMID: 18031511 [PubMed - indexed for MEDLINE]

    PMCID: 2367008

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Verapamil (Calan®, Calan® SR, Covera-HS®, ...)

      Verapamil is used to treat high blood pressure and to control angina (chest pain). The immediate-release tablets are also used alone or with other medications to prevent and treat irregular heartbeats. Verapamil is in a ...